Eyal Grunebaum

Clinician
Division of Immunology and Allergy

Director
Advanced Immunology Management

Senior Scientist
Developmental and Stem Cell Biology

Dr. Grunebaum obtained his medical degree at the Hebrew University, Jerusalem, Israel. After completing pediatric residency at the Schneider’s Children Medical Center in Israel, he pursued a clinical and research fellowship in immunology and allergy as well as hematopoietic stem cell transplantations at The Hospital for Sick Children (SickKids) in Toronto.  

Dr. Grunebaum joined SickKids as a clinician scientist, focusing on the diagnosis, management and understanding of immune abnormalities in children and adults. Using diverse methods, including population studies, cell and animal models, Dr. Grunebaum has contributed to the identification of novel immune defects, development of novel therapies and better appreciation of the immune system in various health and disease states.

Research

Dr. Grunebaum’s research focuses on the immune system in healthy and sick children and adults. Using diverse methods, including population studies, cell and animal models, Dr. Grunebaum studies novel treatments for those born with a faulty immune system that can lead to conditions ranging from severe combined immune deficiency (known as “bubble babies”), children unable to produce appropriate antibodies to fight bacteria and viruses, to teenagers and adults with autoimmune and malignancy diseases.  

Additionally, Dr. Grunebaum investigates causes and management of food allergy and anaphylaxis that occur spontaneously of after various interventions that affect the immune system. Dr. Grunebaum is currently working also on developing better gene and enzyme replacement therapies as well as transplantations of cells capable of reconstituting the immune system. 

Education

• 1980–1983: B.Sc., Hebrew University, Hadassah Medical School, Jerusalem, Israel
• 1980–1988: MD, Doctoral Cum Laude. Hebrew University, Hadassah Medical School, Jerusalem, Israel.
• 1986–1987: Internship, Soroka Medical Center, Beer Sheva and Belinson Medical Center, Israel.
• 1992–1998: Residency in Pediatrics, Hasharon Hospital and Schneider’s Children’s Medical Center, Israel.
• 1994–1998: M.Sc. (Pediatrics), Sackler Faculty of Medicine, School of Continuing Medical Education. Tel-Aviv University, Tel-Aviv, Israel.
• 1998–2001: Clinical and Research fellowship in paediatric immunology and allergy, Division of Allergy & Immunology/ Blood and Marrow Transplant Unit, The Hospital for Sick Children, Toronto

Experience

• 2002: Clinician, Division of Immunology and Allergy Clinician, The Hospital for Sick Children, Toronto, ON
• 2002–2014: Scientist track and Scientist, Infection, Immunity, Injury and Repair and the Developmental and Stem Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, ON
• 2002–2016: Clinician, Blood and Marrow Transplantation unit, The Hospital for Sick Children, Toronto, ON
• 2002: Co-director and director, Advanced Immunology Management (AIM), The Hospital for Sick Children, Toronto, ON
• 2011–2016: Director, Paediatric clinical immunology and allergy training program, The Hospital for Sick Children and University of Toronto, Toronto, ON
• 2012: Chair, Animal Care Committee, The Hospital for Sick Children, Toronto, ON
• 2012–2018: Head, Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, ON
• 2013: Co-Director and director, Food Allergy and Anaphylaxis Program Hospital for Sick Children, Toronto, ON
• 2014: Senior Scientist, Developmental and Stem Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, ON
• 1998–2001: Clinical and Research fellowship in Paediatric Immunology and Allergy, Division of Allergy & Immunology/ Blood and Marrow Transplant Unit, The Hospital for Sick Children, Toronto

1. Toro A, Grunebaum E. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest. 2006;116(10):2717-2726. doi:10.1172/JCI25052
2. Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295(5):508-518. doi:10.1001/jama.295.5.508
3. Papinazath T, Min W, Sujiththa S, et al. Effects of purine nucleoside phosphorylase deficiency on thymocyte development. J Allergy Clin Immunol. 2011;128(4):854-863.e1. doi:10.1016/j.jaci.2011.07.039
4. Dhanju R, Min W, Ackerley C, et al. Pulmonary alveolar proteinosis in adenosine deaminase-deficient mice. J Allergy Clin Immunol. 2014;133(5):1467-1471.e14714. doi:10.1016/j.jaci.2013.11.029doi:10.1016/j.jaci.2012.02.003
5. Kohn DB, Hershfield MS, Puck JM, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019;143(3):852-863. doi:10.1016/j.jaci.2018.08.024